Skip to main content
. 2015 Jul 1;6(19):16926–16938. doi: 10.18632/oncotarget.4700

Figure 3. Combination of chemotherapy and DCMI increases cytotoxic effect on lung CSCs.

Figure 3

A. Viability of lung CSCs treated with 10 μM DCMI alone or in combination with 2.5 μg/ml cisplatin, 50 μM gemcitabine or 30 ng/ml paclitaxel for 48 h (LC1 left side; LC2 right side). Bars shown are the mean ± S.D. of three independent experiments. *P-value <0.05 **P-value <0.01. B. Fold variation of ALDEFLUOR-positive cells in treated lung CSCs with 10 μM DCMI alone or in combination with 2.5 μg/ml cisplatin, 50 μM gemcitabine or 30 ng/ml paclitaxel for 48 h as compared with vehicle-treated controls (LC1 left side; LC2 right side). Bars represent mean ± S.D.; **P-value <0.01 (n = 3).